DexCom stock has delivered a roughly 43.1% decline over the past five years, yet an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach currently points to a sizeable gap between the share price and that estimate. At the same time, the broader valuation checks send a more mixed message, so recent news around product approvals and digital health partnerships is now being weighed against what investors are paying for the stock.

• The roughly 43.1% share price decline over five years means long term holders have seen material capital losses that they may now be reassessing against current valuation signals.
• Recent progress with longer wear Dexcom G7 approval in Canada and participation in the FDA's TEMPO digital health pilot can support revenue and cash flow expectations, while the need to keep investing in new technology and data platforms may limit how much near term free cash flow is available to support equity value.
• DexCom screens as undervalued on an intrinsic basis by about 41.3%, yet with a 3 out of 6 value score and market multiples that look about right, the overall picture is a mixed one rather than a clear bargain.

The issue now is whether DexCom's current share price already reflects these product and digital health developments or if the intrinsic value estimate still offers a meaningful margin of safety.

Is DexCom Still Cheap on Cash Flow?

The Discounted Cash Flow model looks at the cash DexCom is expected to generate for shareholders and discounts it back to today. On this basis, DexCom is valued on cash flows that start from about $1.42b in free cash flow over the last twelve months, with analysts and model estimates assuming that free cash flow continues growing rather than shrinking.

Those cash flows translate into an estimated intrinsic value of about $127 per share, which sits above the current share price and implies the stock is 41.3% undervalued. Dexcom’s recent longer wear G7 approval in Canada is one factor that helps explain why the model assumes continued cash generation from its core continuous glucose monitoring franchise.

Taken together, the DCF work suggests DexCom stock currently screens as undervalued relative to the cash flows implied by today’s business outlook.

Our Discounted Cash Flow (DCF) analysis suggests DexCom is undervalued by 41.3%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

Where Does DexCom Sit on Earnings?

The P/E ratio suits DexCom because earnings are a key focus for many investors in profitable medical equipment companies. DexCom currently trades on a P/E of about 30.9x, compared with a Medical Equipment industry average near 28.8x and a peer group average close to 26.2x. On raw comparison, DexCom stock sits at a modest premium to both its sector and direct peers.

A more tailored fair P/E ratio for DexCom of around 31.5x incorporates factors such as its size, business mix and risk profile. That fair ratio sits slightly above the current market multiple, which points to a valuation that is broadly in line with what those fundamentals might justify rather than a clear discount or an extreme premium.

Overall, DexCom appears roughly fairly valued on its current P/E multiple when set against both the sector and a more customised fair ratio estimate.

The DexCom Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the DexCom valuation puzzle leaves off. They spell out the specific assumptions about DexCom's future growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today's price. Each one focuses on the drivers behind its fair value view so you can compare those expectations with the numbers the company actually reports over time.

DexCom attracts two very different readings from the community, with one side focused on expanded coverage and digital tools and the other on adoption, pricing and execution risk.

Bull case: 13% undervalued

"The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion…"

Bear case: 10% overvalued

"Although broader commercial coverage for type 2 diabetes patients not using insulin, including more than 6 million covered lives across large PBMs and an expected expansion to over 7 million with Prime Therapeutics, supports a larger addressable base, future revenue growth still depends on converting the roughly two thirds of covered patients who are not yet using CGM…"

Do you think there's more to the story for DexCom? Head over to our Community to see what others are saying!

The Bottom Line

DexCom’s Discounted Cash Flow (DCF) work points to a meaningful intrinsic value gap, while the current P/E suggests the market prices the stock roughly in line with peers. That split mostly comes down to how you weigh long term cash flow potential against shorter term sentiment and growth expectations embedded in market multiples. With broader valuation checks sitting in the middle, the key question is whether DexCom can convert its product approvals and broader coverage into durable cash generation without eroding returns through heavier investment. The crux for investors is whether the current discount reflects opportunity or fairly prices the execution and adoption risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.